Prosecution Insights
Last updated: November 12, 2026

Joint Stock Company «Biocad»

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Joint Stock Company «Biocad» has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The company's current prosecution is centralized with no fragmentation across examiners or units. This concentration in 1 distinct art unit and 1 distinct examiner means that the company's current intellectual property effort is centered on a single point of review at the USPTO.

KASAYAN, KATRIEL BARCELLANO is the busiest examiner for the company, holding 1 busiest examiner pending office action. This single action represents the entirety of the 1 pending office action currently active. As the only examiner involved, KASAYAN, KATRIEL BARCELLANO has complete oversight of the company's current filings in the Biotechnology & Pharmaceuticals field. This singular focus allows for a direct and uncomplicated relationship between the applicant and the examiner.

Practitioners should note that the outcome of the company's current prosecution depends entirely on the review of KASAYAN, KATRIEL BARCELLANO within the assigned 1 distinct art unit. There are no other 1 pending office action deadlines or other examiners to coordinate with at this time. This simplicity in the portfolio's distribution reduces the administrative burden but also means that the company's success is tied to a single individual's interpretation of the Biotechnology & Pharmaceuticals technology.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KASAYAN, KATRIEL BARCELLANO 1 25.0% +0.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18689751 INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON KASAYAN, KATRIEL BARCELLANO —

Top Art Units

Art UnitApps
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18689751 INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON KASAYAN, KATRIEL BARCELLANO 1634 §103§112 Non-Final OA — Pending Mar 06, 2024

Managing Joint Stock Company «Biocad»'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Joint Stock Company «Biocad» have?

Joint Stock Company «Biocad» has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Joint Stock Company «Biocad» applications?

Katriel Barcellano Kasayan has the most, with 1 of Joint Stock Company «Biocad»'s pending office actions.

What technology area are Joint Stock Company «Biocad»'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month